Regeneron Pharmaceuticals, Inc. which can be found using ticker (REGN) have now 25 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $1,230.00 and $800.00 with the average target price sitting at $1,078.71. Now with the previous closing price of $767.90 this would indicate that there is a potential upside of 40.5%. It’s also worth noting that there is a 50 day moving average of $882.59 and the 200 day MA is $992.93. The total market capitalization for the company now stands at 85.49B. Currently the stock stands at: $778.00 USD
The potential market cap would be $120,099,012,381 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 19.23, revenue per share of $128.69 and a 7.41% return on assets.
Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. The Company also provides Expresse service assurance and CloudCheck WiFi experience management solutions.
